Neal D. Shore, MD, FACS, discusses the Duravelo-1 and Duravelo-2 trials investigating zelenectide pevedotin in metastatic urothelial carcinoma.
Emerging Novel Therapies in Bladder Cancer
Oncologists detail how zelenectide pevedotin, which is under evaluation in the Duravelo-2 trial, could fill an unmet need in metastatic urothelial carcinoma.
Srikala Sridhar, MD, MSc, FRCPC, discusses the unique application of zelenectide pevedotin, which targets nectin-4 in locally advanced or metastatic urothelial cancer.
Terence Friedlander, MD, spotlights emerging agents of interest in advanced bladder cancer, including the Nectin-4–targeted therapy zelenectide pevedotin.
Terence W. Friedlander, MD, discusses the investigation of BT8009 in the Duravelo-2 study in patients with advanced or metastatic urothelial cancer.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5